The nootropic effect of a dipeptide mimetic of NGF in an experimental model of Alzheimer's disease
- 作者: Volkova A.A.1, Povarnina P.Y.1, Gudasheva T.A.1
-
隶属关系:
- FSBI «V.V. Zakusov Institute of Pharmacology»
- 期: 卷 26, 编号 11 (2023)
- 页面: 60-64
- 栏目: Problems of experimental biology and medicine
- URL: https://journals.eco-vector.com/1560-9596/article/view/623567
- DOI: https://doi.org/10.29296/25877313-2023-11-10
- ID: 623567
如何引用文章
详细
Relevance. The role of nerve growth factor (NGF) deficiency in the pathogenesis of Alzheimer's disease (AD) is well-known. The clinical application of full-size neurotrophin is limited due to its low bioavailability and the risk of adverse effects. At the V.V. Zakusov Institute of Pharmacology, a dimeric dipeptide mimetic of the 4th loop of NGF, compound GK-2 (hexamethylenediamide bis-(N-monosuccinyl-L-glutamyl-L-lysine), was created. It selectively activates specific TrkA receptors and possesses neuroprotective and neuroregenerative properties. Additionally, GK-2 lacks the main side effects of NGF, namely hyperalgesia and weight loss.
The aim of the current study was to investigate the influence of GK-2 on rat memory under the conditions of the scopolamine-induced model of AD.
Material and Methods. Scopolamine was administered intraperitoneally to rats at a dose of 2 mg/kg for 32 days. Simultaneously with scopolamine, animals were intraperitoneally injected with GK-2 at doses of 0.5 and 1 mg/kg. Following the administration of the compounds, a novel object recognition test was conducted to assess both short-term and long-term memory.
Results. Rats receiving scopolamine exhibited a statistically significant decline in long-term memory. The dipeptide GK-2 at a dose of 1 mg/kg completely counteracted the development of this impairment.
Conclusion. The dipeptide mimetic of nerve growth factor, GK-2, shows promise for further investigation as a potential therapeutic agent for the treatment of AD.
全文:
作者简介
A. Volkova
FSBI «V.V. Zakusov Institute of Pharmacology»
Email: volk3012@gmail.com
Post-graduate Student, Department of Human and Animal Physiology, Faculty of Biology, M.V. Lomonosov Moscow State University; Junior Researcher, Department of Medicinal Chemistry
俄罗斯联邦, MoscowP. Povarnina
FSBI «V.V. Zakusov Institute of Pharmacology»
编辑信件的主要联系方式.
Email: povarnina@gmail.com
Ph.D. (Biol.), Senior Researcher, Department of Medicinal Chemistry
俄罗斯联邦, MoscowT. Gudasheva
FSBI «V.V. Zakusov Institute of Pharmacology»
Email: gudasheva@academpharm.ru
Dr.Sc. (Biol.), Professor, Corresponding Member of the Russian Academy of Sciences, Head of the Department of Medicinal Chemistry
俄罗斯联邦, Moscow参考
- Mufson E.J., Counts S.E., Ginsberg S.D. et al. Nerve growth factor pathobiology during the progression of Alzheimer’s disease. Front. Neurosci. 2019; 13: 533.
- Capsoni S., Cattaneo A. On the molecular basis linking nerve growth factor (NGF) to Alzheimer’s disease. Cell. Mol. Neurobiol. 2006; 26(4–6): 617–631.
- Covaceuszach S., Capsoni S., Ugolini G. et al. Development of a non invasive NGF-based therapy for Alzheimer ’ s disease. Curr. Alzheimer Res. 2009; 6(2): 158–170.
- Gu H., Long D., Song C., Li X. Recombinant human NGF-loaded microspheres promote survival of basal forebrain cholinergic neurons and improve memory impairments of spatial learning in the rat model of Alzheimer’s disease with fimbria-fornix lesion. Neurosci. Lett. 2009; 453(3): 204–209.
- Winkler J., Thal L.J. Effects of nerve growth factor treatment on rats with lesions of the nucleus basalis magnocellularis produced by ibotenic acid, quisqualic acid, and AMPA. Exp. Neurol. 1995; 136(2): 234–50.
- Rocco M.L., Soligo M., Manni L., Aloe L. Nerve growth factor: early studies and recent clinical trials. Curr. Neuropharmacol. 2018; 16(10): 1455.
- Gudasheva T.A., Povarnina P.Y., Tarasiuk A.V., Seredenin S.B. Low-molecular mimetics of nerve growth factor and brain-derived neurotrophic factor: design and pharmacological properties. Med. Res. Rev. 2021; (41): 2746–74.
- Nguyen T.V., Shen L., Vander Griend L. et al. Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic dege-neration, and cognitive deficits in AβPP(L/S) transgenic mi-ce. J Alzheimers Dis. 2014; 42(2): 459–483.
- Антипова Т.А., Николаев С.В., Гудашева Т.А. Исследование in vitro нейропротекторных свойств нового оригинального миметика фактора роста нервов ГК-2. Бюллетень экспериментальной биологии и медицины. 2010; 150(11): 537–540 (Antipova T.A., Nikolaev S.V., Gudasheva T.A. Issledo-vanie in vitro nejroprotektornyh svojstv novogo original'nogo mimetika faktora rosta nervov GK-2. Bjulleten' jeksperi-mental'noj biologii i mediciny. 2010; 150(11): 537–540).
- Gudasheva T.A., Povarnina P.Y., Antipova T.A. et al. Dimeric dipeptide mimetics of the nerve growth factor loop 4 and loop 1 activate TRKA with different patterns of intracellular signal transduction. J. Biomed. Sci. 2015; 22(5): 106.
- Faldu K.G., Patel S.S., Shah J.S. Celastrus paniculatus oil ameliorates NF-KB mediated neuroinflammation and synaptic plasticity in the scopolamine-induced cognitive impairment rat model. Metab Brain Dis. 2023; 38(4): 1405–1419.
- Поварнина П.Ю., Воронцова О.Н., Гудашева Т.А. и соавт. Оригинальный дипептидный миметик фактора роста нер-вов ГК-2 восстанавливает нарушенные когнитивные функции в крысиных моделях болезни Альцгеймера. Acta Naturae. 2013; 5(3): 88–95 (Povarnina P.Ju., Voroncova O.N., Gudasheva T.A. i soavt. Original'nyj dipeptidnyj mimetik faktora rosta nervov GK-2 vosstanavlivaet narushennye kognitivnye funkcii v krysinyh modeljah bolezni Al'c-gejmera. Acta Naturae. 2013; 5(3): 88–95).
- Ennaceur A., Delacour J. A new one-trial test for neuro-biological studies of memory in rats. 1: Behavioral Data. Behav. Brain Res. 1988; 31(1): 47–59.
- Beldjoud H., Barsegyan A., Roozendaal B. Noradrenergic activation of the basolateral amygdala enhances object recognition memory and induces chromatin remodeling in the insular cortex. Front. Behav. Neurosci. 2015; 9: 108.
- Волкова А.А., Поварнина П.Ю., Гудашева Т.А., Середе-нин С.Б. Сравнительное изучение мнемотропной активности димерных дипептидных миметиков отдельных петель NGF и BDNF в тесте распознавания нового объекта у крыс. Химико-фармацевтический журнал. 2022; 56(4): 3–6 (Volkova A.A., Povarnina P.Ju., Gudasheva T.A., Serede-nin S.B. Sravnitel'noe izuchenie mnemotropnoj aktiv-nosti dimernyh dipeptidnyh mimetikov otdel'nyh petel' NGF i BDNF v teste raspoznavanija novogo ob’ekta u krys. Himiko-farmacevticheskij zhurnal. 2022; 56(4): 3–6).
- Grayson B., Leger M., Piercy C. et al. Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behav Brain Res. 2015; 285: 176–193.
- Chen W.N., Yeong K.Y. Scopolamine, a toxin-induced experimental model, used for research in alzheimer’s disease. CNS Neurol. Disord. Drug Targets. 2020; 19(2): 85–93.
- Foudah A.I., Devi S., Alam A. et al. Anticholinergic effect of resveratrol with vitamin E on scopolamine-induced Alzheimer's disease in rats: Mechanistic approach to prevent inflammation. Front Pharmacol. 2023; 14: 1115721.
- Reichardt L.F. Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. B Biol. Sci. 2006; 361(1473): 1545–1564.
- Azarafrouz F., Farhangian M., Chavoshinezhad S. et al. Interferon beta attenuates recognition memory impairment and improves brain glucose uptake in a rat model of Alzheimer’s disease: involvement of mitochondrial biogenesis and PI3K pathway. Neuropeptides. 2022; 95: 102262.
- Takada-Takatori Y., Kume T., Sugimoto M. et al. Acetylcholinesterase inhibitors used in treatment of Alzheimer's disease prevent glutamate neurotoxicity via nicotinic acetylcholine receptors and phosphatidylinositol 3-kinase cascade. Neuropharmacology. 2006; 51(3): 474–486.
- Hoeffer CA, Klann E. MTOR Signaling: At the Crossroads of Plasticity, Memory and Disease. Trends Neurosci. 2010; 33(2): 67–75.
- Kirouac L., Rajic A.J., Cribbs D.H., Padmanabhan J. Activation of Ras-ERK Signaling and GSK-3 by Amyloid Precursor Protein and Amyloid Beta Facilitates Neurodegeneration in Alzheimer’s Disease. ENeuro 2017; 4(2): 149–165.